NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Improved tolerability and adherence with enteric coated didanosine capsules (VidexEC) versus buffered tablets (Videx).

Chuck SK, Areff D; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. WePeB5855.

Grady Health System, Atlanta, GA, United States

BACKGROUND: Anecdotally Videx tablets are poorly tolerated resulting in decreased quality of life & sub-optimal adherence. Advantages of VidexEC are less frequent dosing & fewer pills (1 vs 4/day). The objective was to document differences in tolerability & adherence after switching from Videx to VidexEC. METHODS: Pts on VidexEC for >4 wks with prior Videx use were surveyed to examine switching reasons, frequency preference & adherence. Overall satisfaction and the frequency, severity, & bothersomeness of adverse effects were evaluated. RESULTS: Surveyed 50 pts: 41 male; 40+/-7yo; 68% AA; 62% MSM; CD4 361+/-287; VL log 2.8+/-1.1; 6+/-3yr of therapy. Videx & VidexEC durations were 21+/-16mos & 8+/-3mos. Important reasons for switch: fewer pills, ease of taking, more effective, less overall side effects & doctor recommendation. Pts satisfied with: dosing regimen, ease of taking, & effects on daily activities, CD4 & VL. 46% noted increased energy. Adherence: 80% felt decreasing to daily for 1 drug is very helpful. Monthly or more frequent missed doses noted while on Videx & VidexEC in 46% & 8%. 82% noted no missed VidexEC doses in last month & 66% for last 3 mos. Tolerability: 74% noted disagreeable taste of Videx. GI effects occurred less frequently on VidexEC; weekly-daily nausea/vomiting (N/V) (38% vs 8%), bloating/gas pain(32% vs 12%), appetite loss(30% vs 2%), & diarrhea(48% vs 22%). Noted improvements in frequency of bloating/gas pain/appetite loss & N/V/diarrhea in 38-46% & 50-58%. 30-35% had less severe N/V/diarrhea. Diarrhea & N/V bothersomeness decreased in 55% & 80%. Neuropathy prevalence decreased (52% to 38%) with similar daily frequency (20% vs 16%). Decreases in frequency, severity, & bothersomeness of neuropathy noted in 32%, 24%, & 35%. CONCLUSION: Together, an easier dosing regimen & better tolerability with less frequent, less severe, & less bothersome adverse effects are likely explanations for improved adherence with VidexEC.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Antigens, CD4
  • Capsules
  • Diarrhea
  • Didanosine
  • Male
  • Nausea
  • immunology
Other ID:
  • GWAIDS0016898
UI: 102254396

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov